Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00235716 · ClinicalTrials.gov registry record · Phase 3
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease
A Phase 3 study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 3
- Development phase
- 613
- Enrollment target
NCT00235716 is a Phase 3 study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 613 participants.
The verdict
NCT00235716, a Phase 3 study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 613 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether alpha-tocopherol, memantine (Namenda), or the combination will significantly delay clinical progression in mild to moderately demented patients with Alzheimer's disease compared to placebo.
Interventions
- DRUG Placebo
- DRUG Memantine
- DRUG dl-alpha-tocopherol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 613 participants |
| Start Date | 2007-08 |
| Est. Completion | 2012-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00235716
The ClinicalTrials.gov registry entry for NCT00235716 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 613 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00235716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00235716 about?
NCT00235716 is a clinical study titled "A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease". The purpose of this study is to determine whether alpha-tocopherol, memantine (Namenda), or the combination will significantly delay clinical progression in mild to moderately demented patients with Alzheimer's disease compared to placebo.
What is the current status of trial NCT00235716?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 613 participants. The study started on 2007-08. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00235716?
The interventions under investigation include: Placebo (DRUG), Memantine (DRUG), dl-alpha-tocopherol (DRUG).
Who is sponsoring clinical trial NCT00235716?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.